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Background
Second line antiretroviral therapy (ART) was rolled out
in India in December 2008. However, there has been no
study to assess the response to second line ART in
India. This study aims to see the response to the NACO
recommended second line therapy over 24 week period.
Methods
Study was conducted in ART centre, IMS, BHU.
Patients who failed on first line ART (NACO criteria)
were included in the study after consent. Virological,
immunological and clinical response was assessed at 24
weeks. Independent t-test /Mann-Whitney U test was
used for making comparison among the independent
groups. Chi-square test was used to test the association
between categorical variables. Spearman correlation
coefficient was used to measure the degree of associa-
tion between two variables.
Results
Out of 78 patients, only 39 (50%) had virological sup-
pression (viral load<47 copies/ml) and 20 (25.6%) had
partial response (viral load >47-1000), 10 (12.8%) had
viral load >1000 copies/ml and 8 (10.3%) patients died
before 6 months and 1 patient was lost to follow up.
Median increase of CD4 count was 133 cells /ml (IQR
-46-498). Among patients who expired 90% had clinical
failure at baseline, 50% and 18.75% were in stage IV and
III respectively.
Conclusion
Currently recommended second line regimen appears to
be inadequate as large proportion of patients failed to
achieve the desired virological suppression. Our finding
implies a relook at the present second line regimen
recommended by NACO.
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